Source: http://apps.leg.wa.gov/RCW/default.aspx?cite=70.225&full=true
Timestamp: 2018-08-14 23:26:56
Document Index: 28232865

Matched Legal Cases: ['§ 42', '§ 2', '§ 126', '§ 1', '§ 43', '§ 126', '§ 2', '§ 1', '§ 47', '§ 44', '§ 9', '§ 1', '§ 1', '§ 1', '§ 87', '§ 45', '§ 10', '§ 46', '§ 48', '§ 2', '§ 3']

RCWs > Title 70 > Chapter 70.225
Chapter 70.225 RCW
70.225.010 Definitions.
70.225.020 Prescription monitoring program—Subject to funding—Duties of dispensers.
70.225.025 Rules.
70.225.030 Enhancement of program—Feasibility study.
70.225.040 Confidentiality of prescription information—Procedures—Immunity when acting in good faith.
70 . 225 . 045 Annual report.
70.225.050 Department may contract for operation of program.
70.225.060 Violations—Penalties—Disclosure exemption for health care providers.
70 . 225 . 070 Requirements for test sites in the prescription monitoring program.
70 . 225 . 080 Access to data in the qualifying laboratory.
70.225.900 Severability—Subheadings not law—2007 c 259.
70.225.010
[ 2007 c 259 § 42.]
Prescription monitoring program—Subject to funding—Duties of dispensers.
(3) Each dispenser shall submit the information in accordance with transmission methods established by the department.
[ 2013 c 36 § 2; 2013 c 19 § 126; 2012 c 192 § 1; 2007 c 259 § 43.]
Reviser's note: This section was amended by 2013 c 19 § 126 and by 2013 c 36 § 2, each without reference to the other. Both amendments are incorporated in the publication of this section under RCW 1.12.025(2). For rule of construction, see RCW 1.12.025(1).
Findings—2013 c 36: "The legislature finds that:
(1) The prescription monitoring program contributes to patient safety and reduction in drug errors for all patients, including medicaid beneficiaries in Washington state. Further, the prescription monitoring program provides the critical function of reducing costs borne by medicaid and provides for the detection of fraud in the medicaid system.
(2) Because of the nexus between medicaid, medicaid fraud, and cost reductions, the funding for the operations and management of the prescription monitoring program should be funded entirely from the medicaid fraud penalty account under RCW 74.09.215, with the option of funding the prescription monitoring program through voluntary contributions from private individuals and corporations as defined under Title 23, 23B, 24, or 25 RCW." [ 2013 c 36 § 1.]
The department shall adopt rules to implement this chapter.
[ 2007 c 259 § 47.]
70.225.030
Enhancement of program—Feasibility study.
To the extent that funding is provided for such purpose through federal or private grants, or is appropriated by the legislature, the health care authority shall study the feasibility of enhancing the prescription monitoring program established in RCW 70.225.020 in order to improve the quality of state purchased health services by reducing legend drug abuse, reducing duplicative and overprescribing of legend drugs, and improving legend drug prescribing practices. The study shall address the steps necessary to expand the program to allow those who prescribe or dispense prescription drugs to perform a web-based inquiry and obtain real time information regarding the legend drug utilization history of persons for whom they are providing medical or pharmaceutical care when such persons are receiving health services through state purchased health care programs.
[ 2007 c 259 § 44.]
70.225.040
Confidentiality of prescription information—Procedures—Immunity when acting in good faith.
(1) Prescription information submitted to the department must be confidential, in compliance with chapter 70.02 RCW and federal health care information privacy requirements and not subject to disclosure, except as provided in subsections (3), (4), and (5) of this section.
(2) The department must maintain procedures to ensure that the privacy and confidentiality of patients and patient information collected, recorded, transmitted, and maintained is not disclosed to persons except as in subsections (3), (4), and (5) of this section.
(f) The director or the director's designee within the health care authority regarding medicaid clients for the purposes of quality improvement, patient safety, and care coordination. The information may not be used for contracting or value-based purchasing decisions;
(ii) Providing quality improvement feedback to providers, including comparison of their respective data to aggregate data for providers with the same type of license and same specialty; and
(m) A health care provider group of five or more providers for purposes of providing medical or pharmaceutical care to the patients of the provider group, or for quality improvement purposes if:
(i) All the providers in the provider group are licensed by the department or the provider group is operated by the federal government or a federally recognized Indian tribe; and
(5)(a) The department may provide data to public or private entities for statistical, research, or educational purposes after removing information that could be used to identify individual patients, dispensers, prescribers, and persons who received prescriptions from dispensers.
[ 2017 c 297 § 9; 2016 c 104 § 1. Prior: 2015 c 259 § 1; 2015 c 49 § 1; 2011 1st sp.s. c 15 § 87; 2007 c 259 § 45.]
70.225.045
Beginning November 15, 2017, the department shall annually report to the governor and the appropriate committees of the legislature on the number of facilities, entities, or provider groups identified in RCW 70.225.040(3) (l) and (m) that have integrated their federally certified electronic health records with the prescription monitoring program utilizing the state health information exchange.
[ 2017 c 297 § 10.]
70.225.050
Department may contract for operation of program.
The department may contract with another agency of this state or with a private vendor, as necessary, to ensure the effective operation of the prescription monitoring program. Any contractor is bound to comply with the provisions regarding confidentiality of prescription information in RCW 70.225.040 and is subject to the penalties specified in RCW 70.225.060 for unlawful acts.
[ 2007 c 259 § 46.]
70.225.060
Violations—Penalties—Disclosure exemption for health care providers.
(1) A dispenser who knowingly fails to submit prescription monitoring information to the department as required by this chapter or knowingly submits incorrect prescription information is subject to disciplinary action under chapter 18.130 RCW.
(2) A person authorized to have prescription monitoring information under this chapter who knowingly discloses such information in violation of this chapter is subject to civil penalty.
(3) A person authorized to have prescription monitoring information under this chapter who uses such information in a manner or for a purpose in violation of this chapter is subject to civil penalty.
(4) In accordance with chapter 70.02 RCW and federal health care information privacy requirements, any physician or pharmacist authorized to access a patient's prescription monitoring may discuss or release that information to other health care providers involved with the patient in order to provide safe and appropriate care coordination.
[ 2007 c 259 § 48.]
70.225.070
Requirements for test sites in the prescription monitoring program.
(1) Test sites that may receive access to data in the prescription monitoring program under RCW 70.225.040 must be:
(a) Licensed by the department as a test site under chapter 70.42 RCW; and
(b) Certified as a drug testing laboratory by the United States department of health and human services, substance abuse and mental health services administration.
(2) Test sites may not:
(a) Charge a fee for accessing the prescription monitoring program;
(b) Store data accessed from the prescription drug monitoring program in any form, including, but not limited to, hard copies, electronic copies, or web/digital based copies of any kind. Such data may be used only to transmit to those entities listed in *RCW 70.255.040(3)(a).
[ 2015 c 259 § 2.]
*Reviser's note: The reference to RCW 70.255.040 appears to be erroneous. RCW 70.225.040 was apparently intended.
70.225.080
Access to data in the qualifying laboratory.
(1) Access to data in the qualifying laboratory must be under the supervision of the responsible person as designated by the United States department of health and human services, substance abuse and mental health services administration certification program.
(2) Such data cannot be gathered, shared, sold, or used in any manner other than as designated under RCW * 70.255.040, RCW 70.225.070, or this section.
[ 2015 c 259 § 3.]
70.225.900
Severability—Subheadings not law—2007 c 259.
See notes following RCW 41.05.033.